Michael Chorny

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. pmc Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles
    Michael Chorny
    Department of Pediatrics, The Children s Hospital of Philadelphia, Abramson Research Bldg, Ste 702, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Control Release 146:144-51. 2010
  2. pmc Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    FASEB J 27:2198-206. 2013
  3. pmc Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharm Res 29:1232-41. 2012
  4. doi Magnetic nanoparticles for targeted vascular delivery
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA
    IUBMB Life 63:613-20. 2011
  5. ncbi Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    J Biomed Mater Res A 78:276-82. 2006
  6. doi A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles
    Einat Cohen-Sela
    Department of Pharmaceutics, Faculty of Medicine, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Control Release 133:90-5. 2009
  7. pmc Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells
    Michael Chorny
    The Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Mol Pharm 6:1380-7. 2009
  8. pmc Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: implications for gene therapy of restenosis
    Scott P Forbes
    Division of Cardiology, The Children s Hospital of Philadelphia, Abramson Research Center, PA, USA
    Atherosclerosis 230:23-32. 2013
  9. pmc High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents
    Boris Polyak
    Department of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Proc Natl Acad Sci U S A 105:698-703. 2008
  10. pmc Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Methodist Debakey Cardiovasc J 8:23-7. 2012

Collaborators

Detail Information

Publications23

  1. pmc Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles
    Michael Chorny
    Department of Pediatrics, The Children s Hospital of Philadelphia, Abramson Research Bldg, Ste 702, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Control Release 146:144-51. 2010
    ..This protective effect of magnetically targeted MNP impregnated with antioxidant enzymes can be highly relevant for the treatment of cardiovascular disease and should be further investigated in animal models...
  2. pmc Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    FASEB J 27:2198-206. 2013
    ..In conclusion, Ad-loaded MNPs formed by controlled precipitation of zinc oleate represent a novel delivery system, well-suited for efficient, magnetically targeted vascular gene transfer...
  3. pmc Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharm Res 29:1232-41. 2012
    ..This study focused on select variables controlling the uptake and cell compatibility of biodegradable polymer-based MNP in cultured endothelial cells...
  4. doi Magnetic nanoparticles for targeted vascular delivery
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA
    IUBMB Life 63:613-20. 2011
    ..Additional improvements in terms of site specificity and protracted carrier retention at the site of injury may be expected from the development and use of magnetic carriers exhibiting affinity for arterial wall-specific antigens...
  5. ncbi Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    J Biomed Mater Res A 78:276-82. 2006
    ....
  6. doi A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles
    Einat Cohen-Sela
    Department of Pharmaceutics, Faculty of Medicine, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Control Release 133:90-5. 2009
    ..It is concluded that the new technique is advantageous in terms of smaller size, lower size distribution, higher encapsulation yield, and more biocompatible ingredients, with unaltered bioactivity...
  7. pmc Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells
    Michael Chorny
    The Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Mol Pharm 6:1380-7. 2009
    ..The enhancement of adenoviral gene delivery by affinity complexation with biodegradable MNP represents a promising approach with a potential to extend the applicability of the viral gene therapeutic strategies...
  8. pmc Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: implications for gene therapy of restenosis
    Scott P Forbes
    Division of Cardiology, The Children s Hospital of Philadelphia, Abramson Research Center, PA, USA
    Atherosclerosis 230:23-32. 2013
    ....
  9. pmc High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents
    Boris Polyak
    Department of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Proc Natl Acad Sci U S A 105:698-703. 2008
    ....
  10. pmc Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Methodist Debakey Cardiovasc J 8:23-7. 2012
    ..Studies showing the feasibility of this novel targeting strategy in in-stent restenosis models and considerations in the design of carrier formulations for magnetically guided antirestenotic therapy are discussed in this review...
  11. ncbi Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity
    Einat Cohen-Sela
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P O Box 12065, Jerusalem 91120, Israel
    J Pharm Sci 98:1452-62. 2009
    ..The ineffectiveness in the rat restenosis model is probably due to the short depletion period of circulating monocytes and lack of arterial targeting...
  12. pmc Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction
    Ilia Fishbein
    Division of Cardiology, The Children s Hospital of Philadelphia, Abramson Research Center, and Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Biomaterials 34:6938-48. 2013
    ....
  13. ncbi Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    Mol Ther 14:382-91. 2006
    ..It is concluded that Ad-specific affinity tethering to biodegradable NP can significantly increase the level of gene expression via a CAR-independent uptake mechanism...
  14. pmc Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:8346-51. 2010
    ..5 microg PTX/stent). Thus, this study demonstrates the feasibility of site-specific drug delivery to implanted magnetizable stents by uniform field-controlled targeting of MNPs with efficacy for in-stent restenosis...
  15. pmc Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media
    Jillian E Tengood
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104
    Proc Natl Acad Sci U S A 111:4245-50. 2014
    ..contact-inhibited vascular cells. The FRET-based analytical strategy and experimental results reported herein may facilitate the development and inform optimization of biodegradable nanocarriers for cell and drug delivery applications. ..
  16. ncbi Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries
    Shmuel Banai
    Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
    Biomaterials 26:451-61. 2005
    ..The results of this study suggest that locally delivered tyrphostin AGL-2043 formulated in biodegradable NP may be applicable for antirestenotic therapy independent of stent design or type of injury...
  17. pmc Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    FASEB J 21:2510-9. 2007
    ..It is concluded that magnetically driven plasmid DNA delivery can be achieved using biodegradable MNP containing oleate-coated magnetite and surface modified with PEI oleate ion-pair complexes that enable DNA binding...
  18. pmc Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis
    Emanuela Branchetti
    Department of Surgery, Division of Cardiovascular Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19036, USA
    Arterioscler Thromb Vasc Biol 33:e66-74. 2013
    ..Because ROS cause DNA damage and transcriptional activation we investigated the relationship between ROS, DNA damage response, and transdifferentiation of VICs...
  19. ncbi Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Israel
    J Control Release 83:401-14. 2002
    ....
  20. pmc Site-specific gene therapy for cardiovascular disease
    Ilia Fishbein
    The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA 19104, USA
    Curr Opin Drug Discov Devel 13:203-13. 2010
    ..This review summarizes progress made toward the site-specific delivery of cardiovascular gene therapy and highlights selected promising novel approaches...
  21. ncbi Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Israel
    J Control Release 83:389-400. 2002
    ..Nanoprecipitation protocol modifications were suggested to produce nanospheres combining ultrasmall size (<100 nm) with high drug recovery yield, and to reduce the surfactant amount in the formulation...
  22. pmc Targeting to endothelial cells augments the protective effect of novel dual bioactive antioxidant/anti-inflammatory nanoparticles
    Melissa D Howard
    Department of Pharmacology and Center for Targeted Therapeutics and Translational Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
    Mol Pharm 11:2262-70. 2014
    ..This nanoparticle technology may find applicability with drug combinations relevant for other pathologies. ..
  23. ncbi Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries
    Shmuel Banai
    Department of Cardiology, Hadassah University Hospital, P O Box 12000, Jerusalem 91120, Israel
    Cardiovasc Res 64:165-71. 2004
    ..The present study was designed to determine the effect of AGL-2043 delivered from a stent-based, biodegradable polymeric coating on neointima formation in the porcine coronary artery model...